Ecolab's third quarter results showed significant improvement from the second quarter, while still reflecting the divergent impacts of COVID-19 on the business segments. Strong top and bottom line growth in the Healthcare & Life Sciences segment and further strong income growth in the Industrial segment were more than offset by significant declines in the Institutional & Specialty and Other segments.
Third quarter results showed significant improvement from the second quarter, while still reflecting the divergent impacts from COVID-19 on the business segments.
Reported sales from continuing operations decreased 6% from the year-ago period.
Reported diluted EPS from continuing operations was $0.85, a 43% decrease versus last year.
Adjusted diluted EPS from continuing operations were $1.15, a 24% decrease from the comparable period last year.
The continued uncertain outlook regarding the full extent of COVID-19’s impact on the global economy and its longevity do not yet provide an adequate basis for us to provide either quarterly or annual earnings forecasts.
Visualization of income flow from segment revenue to net income